Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration

European Journal of Neurology

Volumn 20, Issue 3, 2013, Pages 420-428

  Steinbrink, F ^a   Evers, S ^a   Buerke, B ^a   Young, P ^a   Arendt, G ^b   Koutsilieri, E ^c   Reichelt, D ^a   Lohmann, H ^a   Husstedt, I W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CSF; HIV infection; HIV associated neurocognitive disorder; MRI; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; VIRUS RNA;

ADULT; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VIRUS LOAD; WHITE MATTER; WHITE MATTER LESION;

AIDS DEMENTIA COMPLEX; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TESTS; TAU PROTEINS;

EID: 84873999231     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12006     Document Type: Article

References (42)

1. AIDS epidemic update 2009 http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf.
2. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
3. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993; 43: 2245-2252.
4. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004; 157: 3-10.
5. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915-1921.
6. Husstedt IW, Frohne L, Böckenholt S, et al. Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross sectional and longitudinal studies of event related potentials. AIDS Res Hum Retrovir 2002; 18: 485-490.
7. Wang T, Gong N, Liu G, Kadiu I. HIV-1-infected astrocytes and the microglial proteome. J Neurimmune Pharmacol 2008; 3: 173-186.
8. Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Op Neurol 2009; 22: 315-320.
9. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4: 543-555.
10. Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Progr Neurobiol 1998; 54: 19-33.
11. Post MJD, Tate LG, Quencer RM, et al. CT, MR and pathology in HIV encephalitis and meningitis. AJR 1988; 151: 373-380.
12. Broderick DF, Wippold FJ II, Clifford DB, et al. White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex. AJR 1993; 161: 177-181.
13. Olson WL, Longo FM, Mills CM, Norman D. White matter disease in AIDS: findings at MR imaging. Radiology 1988; 169: 445-448.
14. Robertson K, Liner J, Heaton R. Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev 2009; 19: 232-249.
15. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27: 86-92.
16. Arendt G, Nolting T, Frisch C, et al. Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease. J Neurovirol 2007; 13: 225-232.
17. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607-613.
18. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689-698.
19. Mastroianni CM, Paoletti F, Valenti C, et al. Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry 1992; 55: 219-221.
20. Cinque P, Vago L, Mengozzi M, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998; 12: 1327-1332.
21. Mildvan D, Spritzler J, Grossberg SE, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 2005; 40: 853-858.
22. 2-microglobulin and neopterin. J Infect Dis 1996; 174: 294-298.
23. Heyes MP, Ellis RJ, Ryan L, et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 2001; 124: 1033-1042.
24. Linerli KJ, Hall CD, Robertson KR. Effects of antiretroviral therapy on cognitive impairment. Curr HIV/AIDS Rep 2008; 5: 64-71.
25. Chang L, Ernst T, Leonido-Yee M, et al. Highly active therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999; 53: 782-789.
26. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63: 2084-2090.
27. Hanning U, Husstedt IW, Niederstadt TU, et al. Cerebral signal intensity abnormalities on T2-weighted MR images in HIV patients with highly active antiretroviral therapy: relationship with clinical parameters and interval changes. Acad Radiol 2011; 18: 1144-1150.
28. Thurnher MM, Schindler EG, Thurnher SA, et al. Highly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging findings and clinical course. AJNR 2000; 21: 670-678.
29. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19: 1367-1374.
30. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995; 168: 231-245.
31. Brew BJ, Pemberton L, Blennow K, et al. CSF amyloid ß42 and tau levels correlate with AIDS dementia complex. Neurology 2005; 65: 1490-1492.
32. Ellis RJ, Seubert P, Mottar R, et al. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. Neurosci Lett 1998; 254: 1-4.
33. Green AJE, Giovannoni G, Hall-Craggs MA, et al. Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Inf 2000; 76: 443-446.
34. Hestad K, McArthur J, Dal Pan G, et al. Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol Scand 1993; 88: 112-118.
35. Hall M, Whaley R, Robertson K, et al. The correlation between neuropsychological and neuroanatomic changes over time in asymptomatic and symptomatic HIV-1-infected individuals. Neurology 1996; 46: 1697-1702.
36. Patel SH, Kolson DL, Glosser G, et al. Correlation between percentage of brain parenchymal volume and neurocognitive performance in HIV-infected patients. AJNR 2002; 23: 543-549.
37. Post MJ, Berger JR, Quencer RM. Asymptomatic and neurologically symptomatic HIV-seropositive individuals: prospective evaluation with cranial MR imaging. Radiology 1991; 178: 131-139.
38. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19: 525-535.
39. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997; 4(Suppl): 85-88.
40. Clifford DB, Fagan AM, Holtzmann DM, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009; 73: 1982-1987.
41. Gisslén M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009; 9: 63.
42. Alisky JM. The coming problem of HIV-associated Alzheimer's disease. Med Hypotheses 2007; 69: 1140-1143.